Trial Profile

Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 27 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
Indications HIV infections
Focus Therapeutic Use
Acronyms FAST

Most Recent Events

20 Jan 2023 Status changed to active, no longer recruiting.
20 Jan 2023 Results of a snapshot analysis reporting safety and efficacy data at week 24 and week 48 published in the Journal of Antimicrobial Chemotherapy
30 Oct 2021 Results presented at the 18th European AIDS Conference

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com